Kisten ras mutations in patients with colorectal cancer: the “RASCAL II” study.
ANDREYEV HJN(Royal Marsden Hospital), Alyson Norman(Royal Marsden Hospital), David Cunningham(Royal Marsden Hospital), J. Oates(Royal Marsden Hospital), Brett R. Dix(The University of Western Australia), Barry Iacopetta(The University of Western Australia), Joanne Young, Thomas J. Walsh(Queensland University of Technology), Robyn L. Ward(St Vincent's Hospital Sydney), Nicholas J. Hawkins(UNSW Sydney), Martin Beránek(Charles University), P Jandı́k(Charles University), Robert Benamouzig(Hôpital Avicenne), Eric Jullian(Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale), Pierre Laurent‐Puig(Inserm), Sylviane Olschwang(Inserm), Oliver Müller(Max Planck Institute of Molecular Physiology), Ilse Hoffman(Max Planck Institute of Molecular Physiology), H. Rabes(Ludwig-Maximilians-Universität München), C Zietz(Ludwig-Maximilians-Universität München), Constantinos Troungos(National and Kapodistrian University of Athens), Christos Valavanis, Siu Tsan Yuen(Queen Mary Hospital), Judy Ho(Queen Mary Hospital), C. T Croke(Royal College of Surgeons in Ireland), D. O’Donoghue(St. Vincent's Birmingham), Walter Giaretti(Alleanza Contro il Cancro), Anna Rapallo(Alleanza Contro il Cancro), Antonio Russo(University of Palermo), Viviana Bazan(University of Palermo), M. Tanaka(Kanazawa University), Kenji Omura(Kanazawa University), ONKUSA T(University of Fukui), FUJIMORI T(Tokyo Medical and Dental University), ONO Y(Dokkyo University), PAULY M(Dokkyo University), FABER C, GLAESENER R, DE GOEIJ AFPM(Centre Hospitalier de Luxembourg), ARENDS JW, ANDERSEN SN, LOVIG T, BREIVIK J, GAUDERNACK G(Norwegian Cancer Society), CLAUSEN OPF(Norwegian Cancer Society), O. P. F. Clausen, MELING GI, ROGNUM TO, SMITH R, GOH H. S(Tan Tock Seng Hospital), FONT A(Tan Tock Seng Hospital), ROSELL R(Hospital Universitari Germans Trias i Pujol), SUN XF(Hospital Universitari Germans Trias i Pujol), ZHANG H(Linköping University), BENHATTAR J, LOSI, Lorena(University Hospital of Lausanne), LEE JQ(University Hospital of Lausanne), WANG ST(National Cheng Kung University), CLARKE PA(National Cheng Kung University), BELL S(Institute of Cancer Research), QUIRKE P(University of Leeds), BUBB VJ(University of Leeds), Vivien J. Bubb(University of Edinburgh), CRUICKSHANK NR, MORTON D(Queen Elizabeth Hospital Birmingham), FOX JC(Queen Elizabeth Hospital Birmingham), AL MULLA F(AstraZeneca (United Kingdom)), LEES N(Cancer Research UK Scotland Institute), HALL CN(Wythenshawe Hospital), SNARY D(Wythenshawe Hospital), WILKINSON K(The Honourable Society of Lincoln's Inn), DILLON D(St Mark's Hospital), COSTA J(Yale University), PRICOLO VE(Yale University), FILKENSTEIN SD(Brown University), THEBO JS(University of Pittsburgh Medical Center), SENAGORE AJ, HALTER SA, WADLER S(Vanderbilt University), MALIK S(Albert Einstein College of Medicine), KRTOLICA K(Albert Einstein College of Medicine), UROSEVIC N.(Chemical Dynamics (United States))
Cited by 889Open Access
Abstract
This collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it predispose to more aggressive biological behaviour in patients with advanced colorectal cancer.
Related Papers
No related papers found
Powered by citation graph analysis